Literature DB >> 11123430

A computational model for quantitative analysis of cell cycle arrest and its contribution to overall growth inhibition by anticancer agents.

H J Kuh1, S Nakagawa, J Usuda, K Yamaoka, N Saijo, K Nishio.   

Abstract

Most anticancer agents induce cell cycle arrest (cytostatic effect) and cell death (cytotoxic effect), resulting in the inhibition of population growth of cancer cells. When asynchronous cells are to be examined, the currently used flow cytometric method can not provide checkpoint-specific and quantitative information on the drug-induced cell cycle arrest. Hence, despite its significance, no good method to analyze in detail the mechanism of cell cycle arrest and its contribution to overall growth inhibition induced by an anticancer agent has yet been established. We describe in this study the development of a discrete time (Markov model)-based computational model for cell cycle progression / arrest with transition probability (TP(i)) as a model parameter. TP(i) was calculated using model equations that include easily measurable parameters such as the fraction of cells in each cell cycle phase and population doubling time. The TP(i) was then used to analyze checkpoint-specific and quantitative changes in cell cycle progression. We also used TP(i) in a Monte-Carlo simulation to predict growth inhibition caused by cell cycle arrest only. Human SCLC cells (SBC-3) exposed to UCN-01 were used to validate the model. The model-predicted growth curves agreed with the observed data for SBC-3 cells not treated or treated at a cytostatic concentration (0.2 mM) of UCN-01, indicating validity of the present model. The changes in TP(i) indicated that UCN-01 reduced the G(1)-to-S transition rate and increased the S-to-G(2) / M and G(2) / M-to-G(1) transition rates of SBC-3 cells in a concentration- and time-dependent manner. When the model-predicted growth curves were compared with the observed data for cells treated at a cytotoxic concentration (2 mM), they suggested that 22% out of 65% and 32% out of 73% of the growth inhibition could be attributed to the cell cycle arrest effect after 48 h and 72 h exposure, respectively. In conclusion, we report here the establishment of a novel method of analysis that can provide checkpoint-specific and quantitative information about cell cycle arrest induced by an anticancer agent and that can be used to assess the contribution of cell cycle arrest effect to the overall growth inhibition.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11123430      PMCID: PMC5926310          DOI: 10.1111/j.1349-7006.2000.tb00918.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  19 in total

1.  Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells.

Authors:  C M Seynaeve; M Stetler-Stevenson; S Sebers; G Kaur; E A Sausville; P J Worland
Journal:  Cancer Res       Date:  1993-05-01       Impact factor: 12.701

2.  Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function.

Authors:  R G Shao; C X Cao; T Shimizu; P M O'Connor; K W Kohn; Y Pommier
Journal:  Cancer Res       Date:  1997-09-15       Impact factor: 12.701

3.  Do cells cycle?

Authors:  J A Smith; L Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1973-04       Impact factor: 11.205

4.  Cell size, cell cycle and transition probability in mouse fibroblasts.

Authors:  R Shields; R F Brooks; P N Riddle; D F Capellaro; D Delia
Journal:  Cell       Date:  1978-10       Impact factor: 41.582

5.  Further evidence for a random transition in the cell cycle.

Authors:  R Shields
Journal:  Nature       Date:  1978-06-29       Impact factor: 49.962

Review 6.  Apoptosis, p53, and tumor cell sensitivity to anticancer agents.

Authors:  J M Brown; B G Wouters
Journal:  Cancer Res       Date:  1999-04-01       Impact factor: 12.701

7.  Possible mechanisms of paclitaxel-induced apoptosis.

Authors:  W Fan
Journal:  Biochem Pharmacol       Date:  1999-06-01       Impact factor: 5.858

8.  UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.

Authors:  Q Wang; S Fan; A Eastman; P J Worland; E A Sausville; P M O'Connor
Journal:  J Natl Cancer Inst       Date:  1996-07-17       Impact factor: 13.506

9.  UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line.

Authors:  K Kawakami; H Futami; J Takahara; K Yamaguchi
Journal:  Biochem Biophys Res Commun       Date:  1996-02-27       Impact factor: 3.575

10.  Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models.

Authors:  E A Sausville; R D Lush; D Headlee; A C Smith; W D Figg; S G Arbuck; A M Senderowicz; E Fuse; H Tanii; T Kuwabara; S Kobayashi
Journal:  Cancer Chemother Pharmacol       Date:  1998       Impact factor: 3.333

View more
  3 in total

1.  Anticancer Profiling for Coumarins and Related O-Naphthoquinones from Mansonia gagei against Solid Tumor Cells In Vitro.

Authors:  Mohammed A Baghdadi; Fahad A Al-Abbasi; Ali M El-Halawany; Ali H Aseeri; Ahmed M Al-Abd
Journal:  Molecules       Date:  2018-04-26       Impact factor: 4.411

2.  Bioactive glycoalkaloides isolated from Solanum melongena fruit peels with potential anticancer properties against hepatocellular carcinoma cells.

Authors:  Mostafa I Fekry; Shahira M Ezzat; Maha M Salama; Ohoud Y Alshehri; Ahmed M Al-Abd
Journal:  Sci Rep       Date:  2019-02-11       Impact factor: 4.379

3.  Design and Characterization of Atorvastatin Dry Powder Formulation as a potential Lung Cancer Treatment.

Authors:  Alaa S Tulbah; Amr Gamal
Journal:  Saudi Pharm J       Date:  2021-11-11       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.